It is the time of big promise in the diagnosis and treatment of Alzheimer’s Disease (AD). There are dozens of genetic risks discovered in recent years. There are also emerging blood tests whose performance in diverse groups of patients is currently being confirmed. New disease-modifying drugs help to remove beta-amyloid plaques from the brain. While AD is a complex disease and its onset is connected to multiple biochemical pathways in cells, the new treatments target a core component of Alzheimer’s Disease.

In this episode of NeuroCentury, its host Paweł Świeboda talks to Professor Stephen Salloway, one of the leading scholars working on biomarkers and drug development for prevention and early treatment of Alzheimer’s Disease. He is Professor of Psychiatry and Human Behaviour and Professor of Neurology at Brown University. He is also Founding Director of the Memory and Ageing Program at Butler Hospital.

The conversation helps to disentangle what the new era in diagnosis and treatment of AD can bring, with the advent of monoclonal antibodies and the emergence of new generation brain health services. Rethinking the care journey is part of the process, since treatments need to start before symptoms emerge, or possibly even before the amyloid build-up. Future discovery research will go beyond lowering of amyloid levels to have an even bigger impact on the disease.

#neurocentury #AD #Alzheimer’sDisease #brain #brainhealth

______________

neurocentury.com

Music for the NeuroCentury podcast is composed by Rafał Kulczycki